Objective: To explore the correlation between the Cdx2 expression and clinicopathologic features of patients with gastric carcinoma, and to evaluate the role of Cdx2 as a prognostic indicator of gastric carcinoma. Methods: The expression of Cdx2 was studied using immunohistochemistry of paraffin-embedded tumor specimens from 154 patients who underwent D2 resection for gastric adenocarcinoma from 1994 to 1998. Results: Cdx2 expression was detected in 35.1% (54 of 154) of gastric carcinoma cases. Expression of Cdx2 was significantly higher in intestinal-type carcinomas than in diffuse-type carcinomas, and in cases with TNM stage Ⅰ and Ⅱ than those with TNM stage Ⅲ and Ⅳ (P＜0.001 and P=0.012, respectively).There was a clear negative correlation between Cdx2 expression and lymph node metastasis (P=0.049). The patients with Cdx2-positive expression showed higher survival rate than those with Cdx2-negative expression (P＜0.0001). Multivariate analysis revealed that the expression of Cdx2 was the independent prognostic indicator in this series (P＜0.001). Conclusion:These data suggest that Cdx2 has significant value in predicting prognosis of gastric carcinoma.